DK590288D0 - Kemiske forbindelser - Google Patents

Kemiske forbindelser

Info

Publication number
DK590288D0
DK590288D0 DK590288A DK590288A DK590288D0 DK 590288 D0 DK590288 D0 DK 590288D0 DK 590288 A DK590288 A DK 590288A DK 590288 A DK590288 A DK 590288A DK 590288 D0 DK590288 D0 DK 590288D0
Authority
DK
Denmark
Prior art keywords
pellet
supernatant
fraction
components
new
Prior art date
Application number
DK590288A
Other languages
English (en)
Inventor
Alan G Barbour
Sven Bergstroem
Louis Magnarelli
Original Assignee
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8146053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK590288(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of DK590288D0 publication Critical patent/DK590288D0/da
Priority to DK590288A priority Critical patent/DK590288D0/da
Application filed by Symbicom Ab filed Critical Symbicom Ab
Priority to PCT/DK1989/000248 priority patent/WO1990004411A1/en
Priority to AT00125910T priority patent/ATE432988T1/de
Priority to EP89912228A priority patent/EP0445135B1/en
Priority to EP95203128A priority patent/EP0711563B1/en
Priority to DE68929550T priority patent/DE68929550T2/de
Priority to AU44953/89A priority patent/AU639667B2/en
Priority to AT93201345T priority patent/ATE212376T1/de
Priority to DE68929369T priority patent/DE68929369T2/de
Priority to EP00125910A priority patent/EP1092774B1/en
Priority to DE68929565T priority patent/DE68929565D1/de
Priority to CA002001328A priority patent/CA2001328C/en
Priority to EP93201345A priority patent/EP0565208B1/en
Priority to DE68927891T priority patent/DE68927891T2/de
Priority to AT89912228T priority patent/ATE150318T1/de
Priority to DK199100750A priority patent/DK175844B1/da
Priority to NO91911602A priority patent/NO911602L/no
Priority to FI911964A priority patent/FI112366B/fi
Priority to US08/137,175 priority patent/US5777095A/en
Priority to US08/079,601 priority patent/US5523089A/en
Priority to US08/262,220 priority patent/US6054296A/en
Priority to US08/264,036 priority patent/US6300101B1/en
Priority to US08/320,416 priority patent/US5582990A/en
Priority to US08/375,993 priority patent/US5688512A/en
Priority to US08/479,017 priority patent/US6143872A/en
Priority to US08/470,638 priority patent/US6509017B1/en
Priority to US08/471,019 priority patent/US6083722A/en
Priority to US08/470,627 priority patent/US6203798B1/en
Priority to US08/466,393 priority patent/US6183986B1/en
Priority to US08/588,637 priority patent/US7094391B1/en
Priority to PCT/US1997/000557 priority patent/WO1997026006A1/en
Priority to AU17470/97A priority patent/AU740048B2/en
Priority to FI981624A priority patent/FI981624A7/fi
Priority to JP9526117A priority patent/JP2000507209A/ja
Priority to EP97904758A priority patent/EP0876156A4/en
Priority to IL12532397A priority patent/IL125323A0/xx
Priority to ZA9700459A priority patent/ZA97459B/xx
Priority to NO983220A priority patent/NO983220L/no
Priority to US09/973,406 priority patent/US6814970B2/en
Priority to DK200401413A priority patent/DK200401413A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK590288A 1919-10-24 1988-10-24 Kemiske forbindelser DK590288D0 (da)

Priority Applications (40)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser
DE68927891T DE68927891T2 (de) 1988-10-24 1989-10-24 Fraktionen von BORELLA BURGDORFERI mit immunogener Wirkung
AT89912228T ATE150318T1 (de) 1988-10-24 1989-10-24 Fraktionen von borella burgdorferi mit immunogener wirkung
AT93201345T ATE212376T1 (de) 1988-10-24 1989-10-24 Dns fragmente, die für borrelia burgdorferi ospa kodieren, verfahren zur herstellung von ospa polypeptiden, und diagnostische verfahren basierend auf diesen dns fragmenten
DE68929565T DE68929565D1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA Polypeptid zur Immunisierung gegen Lymeborreliose
EP89912228A EP0445135B1 (en) 1988-10-24 1989-10-24 Immogenically active fractions of borrelia burgdorferi
EP95203128A EP0711563B1 (en) 1988-10-24 1989-10-24 Substantially pure entire ospa protein free from other b. burgdorferi related material
DE68929550T DE68929550T2 (de) 1988-10-24 1989-10-24 Im Wesentlichen reines ganzes OspaA-Protein, frei von anderen B. burgdorferi-Materialien
AU44953/89A AU639667B2 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi
PCT/DK1989/000248 WO1990004411A1 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi
DE68929369T DE68929369T2 (de) 1988-10-24 1989-10-24 DNS Fragmente, die für Borrelia burgdorferi OspA kodieren, Verfahren zur Herstellung von OspA Polypeptiden, und diagnostische Verfahren basierend auf diesen DNS Fragmenten
EP00125910A EP1092774B1 (en) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA polypeptide for immunization against Lyme disease
AT00125910T ATE432988T1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi ospa polypeptid zur immunisierung gegen lymeborreliose
CA002001328A CA2001328C (en) 1988-10-24 1989-10-24 Borrelia antigen
EP93201345A EP0565208B1 (en) 1988-10-24 1989-10-24 DNA fragments encoding OspA of Borrelia burgdorferi, method of preparation of OspA polypeptides and diagnostic methods based upon said DNA fragments
FI911964A FI112366B (fi) 1988-10-24 1991-04-23 Menetelmä organismin Borrelia burgdorferi OspA -polypeptidin ja sitä tuottavan organismin valmistamiseksi ja menetelmässä käytettäviä välineitä
NO91911602A NO911602L (no) 1988-10-24 1991-04-23 Immunogent aktive fraksjoner av borrelia burgdorferi.
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
US08/137,175 US5777095A (en) 1988-10-24 1992-10-22 Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US08/079,601 US5523089A (en) 1988-10-24 1993-06-22 Borrelia antigen
US08/262,220 US6054296A (en) 1988-10-24 1994-06-20 66 kDa antigen from Borrelia
US08/264,036 US6300101B1 (en) 1988-10-24 1994-06-22 Methods and compositions including a 13kD B. burgdorferi protein
US08/320,416 US5582990A (en) 1988-10-24 1994-10-03 DNA encoding borrelia burgdorferi OspA and a method for diagnosing borrelia burgdorferi infection
US08/375,993 US5688512A (en) 1988-10-22 1995-01-20 Borrelia antigen
US08/479,017 US6143872A (en) 1988-10-24 1995-06-06 Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US08/470,638 US6509017B1 (en) 1919-10-24 1995-06-06 66 KDA antigen from Borrelia
US08/471,019 US6083722A (en) 1988-10-24 1995-06-06 Borrelia antigen
US08/470,627 US6203798B1 (en) 1988-10-24 1995-06-06 Borrelia antigen
US08/466,393 US6183986B1 (en) 1988-10-24 1995-06-06 OspA DNA and lyme disease vaccine
US08/588,637 US7094391B1 (en) 1988-10-24 1996-01-19 Compositions and methods for administering Borrelia burgdorferi antigens
IL12532397A IL125323A0 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
EP97904758A EP0876156A4 (en) 1988-10-24 1997-01-17 COMPOSITIONS AND METHODS FOR THE APPLICATION OF ANTIGENS FOR BORRELIA BURGDORFERI
PCT/US1997/000557 WO1997026006A1 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
AU17470/97A AU740048B2 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
FI981624A FI981624A7 (fi) 1988-10-24 1997-01-17 Koostumukset ja menetelmät Borrelia burgdorferi antigeenien annostelem iseksi
JP9526117A JP2000507209A (ja) 1988-10-24 1997-01-17 ボレリア・ブルグドフェリ（Ｂｏｒｒｅｌｉａ ｂｕｒｇｄｏｒｆｅｒｉ）抗原を投与するための組成物および方法
ZA9700459A ZA97459B (en) 1988-10-24 1997-01-20 Composition and methods for administering borrelia burgdorferi antigens.
NO983220A NO983220L (no) 1988-10-24 1998-07-13 Sammensetninger og fremgangsmåter for å administrere Borrelia Burgdorferi-antigener
US09/973,406 US6814970B2 (en) 1988-10-24 2001-10-09 Methods and compositions including a 13 kD B. burgdorferi protein
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser

Publications (1)

Publication Number Publication Date
DK590288D0 true DK590288D0 (da) 1988-10-24

Family

ID=8146053

Family Applications (3)

Application Number Title Priority Date Filing Date
DK590288A DK590288D0 (da) 1919-10-24 1988-10-24 Kemiske forbindelser
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Country Status (10)

Country Link
US (6) US5523089A (da)
EP (4) EP1092774B1 (da)
AT (3) ATE150318T1 (da)
AU (1) AU639667B2 (da)
CA (1) CA2001328C (da)
DE (4) DE68927891T2 (da)
DK (3) DK590288D0 (da)
FI (1) FI112366B (da)
NO (1) NO911602L (da)
WO (1) WO1990004411A1 (da)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054296A (en) * 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6300101B1 (en) 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
ZA907419B (en) * 1989-09-19 1991-07-31 Max Planck Gesellschaft Vaccine against lyme disease
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5470712A (en) * 1990-03-05 1995-11-28 Us Health Antigenic proteins of Borrelia burgdorferi
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
EP0465204B1 (en) * 1990-07-06 2000-09-20 American Home Products Corporation Vaccine against Lyme disease
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US5436000A (en) * 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
JPH06508689A (ja) * 1991-06-13 1994-09-29 パシフィック・バイオテック・インコーポレイテッド 特異的リガンドを検出するための検定
US5324630A (en) * 1991-06-28 1994-06-28 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
DK0598816T3 (da) * 1991-08-15 1999-11-22 Deutsches Krebsforsch Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
CA2121121C (en) * 1991-10-18 2003-06-10 Lorne F. Erdile Preparation of recombinant borrelia proteins
DK0650527T3 (da) * 1991-10-22 2003-07-14 Symbicom Ab Forbedring af Borrelia burgdorferidiagnose og -profylakse
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5308753A (en) * 1992-02-20 1994-05-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for purifying and detecting IGM antibodies
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
BE1006728A3 (fr) * 1993-02-19 1994-11-29 Wallone Region Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi.
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
ATE329615T1 (de) * 1994-04-11 2006-07-15 Wyeth Corp Borrelia burgdorferi bacterin
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
CA2223433C (en) * 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
WO1997042325A1 (en) * 1996-05-08 1997-11-13 Yale University B. burgdorferi polypeptides expressed in vivo
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6902893B1 (en) * 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
CA2294568A1 (en) * 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Lyme disease vaccines
EP1012181B1 (en) 1997-06-30 2006-08-23 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
EP1012269A2 (en) * 1997-09-10 2000-06-28 Symbicom Ab P13 antigens from borrelia
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
AU4800500A (en) * 1999-06-21 2001-01-09 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
EP1287360A2 (de) * 2000-06-02 2003-03-05 Zeptosens AG Kit und verfahren zur multianalytbestimmung
PT1311540E (pt) * 2000-08-18 2008-03-20 Univ New York State Res Found Ospa de borrelia burgdorferi modificada
US20040033623A1 (en) * 2002-08-16 2004-02-19 Igenex, Inc. Assay for detection of antigen in bodily fluid
WO2004103269A2 (en) * 2002-10-18 2004-12-02 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP1613641B1 (en) 2003-04-02 2009-01-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
US20060051060A1 (en) * 2003-07-03 2006-03-09 Henry Dorovanessian Method and system for digitally recording broadcast content
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US20060281139A1 (en) * 2005-05-23 2006-12-14 Viramed Biotech Ag Carrier and method for the detection of anti-borrelia antibodies and test kit for use in the diagnosis of Lyme borreliosis infections
US7663212B2 (en) 2006-03-21 2010-02-16 Infineon Technologies Ag Electronic component having exposed surfaces
US7541681B2 (en) * 2006-05-04 2009-06-02 Infineon Technologies Ag Interconnection structure, electronic component and method of manufacturing the same
CN101573135B (zh) 2006-11-03 2013-06-12 先灵-普劳有限公司 犬莱姆病疫苗
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2283138A4 (en) * 2008-04-09 2011-05-11 Ventria Bioscience OSPA PRODUCTION FOR THE FIGHT AGAINST LYME DISEASE
CA2723226A1 (en) 2008-05-02 2009-05-11 Cancer Research Technology Ltd Products and methods for stimulating an immune response
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
EA025280B1 (ru) 2010-03-09 2016-12-30 Амир Максютов Полиэпитопные конструкции и способы их получения и применения
CN107641151B (zh) 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
KR20130101067A (ko) 2010-09-27 2013-09-12 코넬 유니버시티 라임병의 진단 방법
WO2012047970A1 (en) * 2010-10-05 2012-04-12 Board Of Trustees Of Michigan State University Regulatory factors controlling oil biosynthesis in microalgae and their use
RU2015106742A (ru) 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения
EP3259588A4 (en) * 2015-02-17 2018-07-11 Colorado State University Research Foundation High sensitivity method for early lyme disease detection
JP7089479B2 (ja) 2016-04-14 2022-06-22 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 抗菌性ポリアミド又はオクテニジン保存剤を含むマルチドーズ組成物
WO2018227109A1 (en) 2017-06-08 2018-12-13 Colorado State University Research Foundation Differentiation of lyme disease and southern tick-associated rash illness
EP3898666A2 (en) 2018-12-17 2021-10-27 Immudex ApS Panel comprising borrelia mhc multimers
CN119584978A (zh) 2022-06-07 2025-03-07 再生元制药公司 用于调节t细胞活性的多特异性分子及其用途
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4888276A (en) * 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit

Also Published As

Publication number Publication date
EP0711563B1 (en) 2007-01-17
ATE150318T1 (de) 1997-04-15
EP0711563A1 (en) 1996-05-15
EP1092774A2 (en) 2001-04-18
DK75091A (da) 1991-06-12
DE68929550T2 (de) 2007-12-06
DE68927891T2 (de) 1997-10-02
CA2001328A1 (en) 1991-04-24
DE68929565D1 (de) 2009-07-16
EP1092774B1 (en) 2009-06-03
AU4495389A (en) 1990-05-14
DE68929369T2 (de) 2002-09-26
DK75091D0 (da) 1991-04-23
US5582990A (en) 1996-12-10
ATE212376T1 (de) 2002-02-15
EP0445135B1 (en) 1997-03-19
US6203798B1 (en) 2001-03-20
DE68927891D1 (de) 1997-04-24
EP0445135A1 (en) 1991-09-11
EP1092774A3 (en) 2001-04-25
CA2001328C (en) 2005-12-13
DK200401413A (da) 2004-09-17
EP0565208B1 (en) 2002-01-23
EP0565208A1 (en) 1993-10-13
US6083722A (en) 2000-07-04
AU639667B2 (en) 1993-08-05
WO1990004411A1 (en) 1990-05-03
US5688512A (en) 1997-11-18
DE68929369D1 (de) 2002-03-14
NO911602D0 (no) 1991-04-23
US6183986B1 (en) 2001-02-06
FI911964A0 (fi) 1991-04-23
NO911602L (no) 1991-06-24
FI112366B (fi) 2003-11-28
DE68929550D1 (de) 2007-03-08
ATE432988T1 (de) 2009-06-15
DK175844B1 (da) 2005-03-29
US5523089A (en) 1996-06-04

Similar Documents

Publication Publication Date Title
DK590288D0 (da) Kemiske forbindelser
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
CA2149319A1 (en) Haemophilus outer membrane protein
ATE544776T1 (de) Chimäre dna-bindeproteine
GR72953B (da)
EP0338767A3 (en) Novel recombinant and chimeric antibodies directed against a human adenocarcinoma antigen
HUP9800730A2 (hu) Expressziós rendszer heterológ antigének fúziós proteinként történő expresszáltatására
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
ES2147178T3 (es) Dominio de union a cd2 del antigeno 3 asociado con la funcion linfocitica.
IL65565A (en) Plasmids coding for b.thuringiensis crystal protein,their production and their use in creating genetically engineered bacterial strains
ATE387458T1 (de) Fas-antigenbindender ligand
EP0185076A4 (da)
FR2669338B1 (da)
Clezardin et al. Isolation of thrombospondin released from thrombinstimulated human platelets by fast protein liquid chromatography on an anion-exchange mono-q column
EP0331356A3 (en) Expression of hiv binding proteins
FI970428A0 (fi) Soluja, joissa on CD4-houkutusreseptoreita ja vastaavia molekyylejä ja menetelmiä
Takenaka et al. Royal jelly from Apis cerana japonica and Apis mellifera
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
DE3788993D1 (de) Rekombinante Ligninase.
Reeves et al. Partial purification and characterization of the multiple molecular forms of staphylococcal clotting activity (coagulase)
Guerillon et al. Crossed immunoelectrophoretic characterization of Chilo iridescent virus surface antigens
WO1997026361A3 (en) Bacterial donor cell useful in conjugation
WO1998031796A8 (en) Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
RU96124779A (ru) Днк, кодирующая кератиназу bacilus licheniformis pwd-1

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment